In an increasingly interconnected global marketplace, understanding and adapting to the nuances of different markets is crucial for Market Access success. Our company supports pharma, biotech and medtech clients with Global Market Access and country-specific solutions in major markets such as the United States, France, Germany, Italy, Spain, Switzerland and the United Kingdom. Our agency Justin Stindt Consultants consists of experts with both Global Market Access expertise and local experience in all major markets. Our consultancy also has a broad network of local experts and partners in all major international markets to provide global solutions to our clients.
In each of these markets, our consulting firm leverages our expertise to tailor market access strategies that address specific challenges in each market while guaranteeing consistency with global strategy.
For more information on market access in a specific market (EU or US), click the links below:
Justin Stindt Consultants is your agency to support you with global Market Access
Justin Stindt Consultants is your consulting firm with experts who have extensive experience in Market Access in international markets. Our skilled consultants can help you with market access activities such as pricing and reimbursement strategies, funding pathways, early advice meetings, pricing negotiations, ad boards, early access programme feasibility assessments and dossier submissions, pricing and reimbursement dossier preparations and submissions etc.
For more information about the services our agency provides, go to Pricing & Reimbursement Strategy, Pricing & Reimbursement Dossiers, Payer & HTA Engagement.
Industries
Pharma
The Pharma industry is characterized by long research & development cycles and complex Market Access, but once successful, medicines can achieve universal reimbursement.
Biotech
The biotech industry faces largely the same challenges & opportunities as the pharma industry but in addition to this financing rounds and Business Development & Licensing discussions play a pivotal role on the road towards successful Market Access.
Medical Devices
While regulatory approval is typically faster for Medical Devices compared to medicines, Pricing & Reimbursement is typically more complex and fragmented. Market Access for Medical Devices is a dynamic process which needs to be strategically managed throughout the product lifecycle.
e-Health / Digital Health
Market Access pathways for E-Health / Digital Health solutions are emerging and span from pilot projects to regular reimbursement pathways in key markets.
Our News
Joint Clinical Assessment (JCA) in the EU: The European Commission adopted the Implementing Act on Joint Clinical Assessment
The implementation of the Joint Clinical Assessment (JCA) in the European Union represents a notable step forward in assessing innovative therapies across the member states.
Germany’s New 2024 Medical Research Act Law
On July 4, 2024, the Bundestag (German Parliament) passed significant amendments to the country’s drug pricing and reimbursement laws as part of the new Medical
2024 List and Net Pricing Strategies EU-5
What you need to know about confidential discounts and net prices in EU-5 In the EU-5 (France, Germany, Italy, Spain, and the UK), the differentiation
Key insights from the new draft regulation on the communication with the European Medicines Agency
The new Joint Clinical Assessment (JCA) and Joint Scientific Consultation (JSC) initiatives, which are part of the European-wide Health Technology Assessment (HTA) reform, support the
The US Inflation Reduction Act – key changes to Pricing & Reimbursement of medicines in the USA you need to know about
The Inflation Reduction Act (IRA), signed into law in August 2022, is a piece of legislation aimed at addressing several critical issues facing the United
French 2024 early access program covers 330+ innovative treatments
France’s Reimbursed Early Access Programs (EAP) allow for reimbursement of new drugs and medicines before traditional reimbursement making it a very attractive option for pharma
